Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

http://www.wikidata.org/entity/Q34431300

about

Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations.Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.Natalizumab in Multiple Sclerosis: Long-Term Management.Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.Natalizumab in the pediatric MS population: results of the Italian registry Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Halo and spillover effect illustrations for selected beneficial medical devices and drugs.Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.Autologous hematopoietic cell transplantation in multiple sclerosis.Treatment decisions in multiple sclerosis - insights from real-world observational studies.Natalizumab treatment of multiple sclerosis: new insights.Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta/Glatiramer Acetate Therapies: A NARCOMS Analysis.Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.The importance of collecting structured clinical information on multiple sclerosis.Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.Pharmacological and non-pharmacological therapies of cognitive impairment in multiple sclerosis.

P2860

Q26748229-520038FA-DF15-4A32-98D0-914EF4BF4A5B Q27009769-D375ABB6-AA8F-40DC-8596-D49B9A602AC8 Q30993770-0F739C39-2128-4EE6-A02B-5E0937254724 Q33736198-74C7B47C-A74D-4CD4-A632-409898CD23A6 Q33754882-E785862E-1B88-4825-97A2-AB2046953234 Q33814485-2E462550-5271-4537-8832-BA5B44DC7485 Q33825885-42FF23B7-1B61-4258-9AAD-D0F9FBBBD573 Q33891255-EE6EB545-39EB-430C-8A2C-75CA7CDEDD8E Q34803324-394F4219-42D3-4D74-AB6B-05C83499B973 Q35469575-5EF90704-32BE-4105-B5A4-BF8BD9203345 Q35684256-8E844AC1-39B6-4E98-A36C-B7404AF4D623 Q35788938-D3C1BDD4-F48B-46B0-9663-C89B7C5B8BD3 Q35884067-A3F42CC4-7FAD-4717-8AF2-EB2911169289 Q35895287-79A36036-6D57-465B-A54C-A964E4431AF3 Q36073992-8CF763AD-58D2-40B9-BF7A-B9AFAD60626A Q36133467-15F4002A-1492-489D-BDE6-5CC5AFA3EB12 Q36484448-74B722C2-D4A5-4DE5-8A4D-DCB8469A8624 Q36789883-4602F71E-A026-449F-AE2C-7AA66144132F Q38364547-E94D24F4-08F7-4366-9B22-793EA4D4348C Q38371740-689761DD-C51C-4E25-BD10-957686B2AF60 Q38616689-3777D1A4-392C-428A-8978-CE7C56E0CED0 Q38619288-47EAA567-03D4-42BC-B2EA-AAE690479DCE Q38636586-BB32CD05-1962-4345-BAAB-F01C7F0151B2 Q38758444-42D59AEA-3A66-4CE2-8FF5-A8724BB52B2A Q38818703-BE9B9FDB-C851-45C0-B6FF-11C52EDEB301 Q39022643-19EEA9F7-D9A0-4AB2-B7C5-A0309544B0D0 Q39048568-500B8AA5-2B9F-4DBA-8124-26404AA56521 Q39269762-08AFAA91-1CAD-4BAA-8A04-DC20DB0CE905 Q39732691-86C3E113-B4CA-48F4-ACF5-047A0C599FFA Q40061894-C64EAE64-D1DD-4193-84FE-C74FFA956D6B Q40498719-60223258-6BF8-49AA-9DAE-CB230023AFA6 Q40619670-56FC08DA-7D2C-4E33-BE50-143D7566CCF4 Q41126166-36BAEFF6-6C01-47EA-8734-6228762EF010 Q41386664-10DC3188-FBAF-47F4-BA60-6ABC1C396C3B Q41626879-65760456-0E47-4604-80BC-F87EAB7ED39E Q42665193-FEA226A3-4E94-43E1-9FC2-644E4A845643 Q42747344-98BA19A7-237A-477B-AEC0-F4FD1A2EC0B1 Q47148150-66304A8D-2ABF-4B96-B63C-93D836E82B04 Q47198260-610EE745-0DC8-44AB-AA41-D88E9906619F Q47978062-A2D84389-CBA8-4284-AB0B-F365CE2D2B02

P2860

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

http://www.wikidata.org/entity/Q34431300

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Efficacy and safety of nataliz ...... servational programme results.

@ast

Efficacy and safety of nataliz ...... servational programme results.

@en

Efficacy and safety of nataliz ...... servational programme results.

@nl

type

label

Efficacy and safety of nataliz ...... servational programme results.

@ast

Efficacy and safety of nataliz ...... servational programme results.

@en

Efficacy and safety of nataliz ...... servational programme results.

@nl

prefLabel

Efficacy and safety of nataliz ...... servational programme results.

@ast

Efficacy and safety of nataliz ...... servational programme results.

@en

Efficacy and safety of nataliz ...... servational programme results.

@nl

P1433

Q34431300-A1F407F8-4BC3-4DA3-AFB5-5AAA4002DC2F

P1476

Q34431300-8720B5A3-4CC7-414F-961A-06A3348CD38C

P2093

Q34431300-149FBEC0-6AFB-4205-B4AF-0F3A73E2FAED

Q34431300-25A9DE5A-C702-4CC8-B926-2619A3D72648

Q34431300-28CB1B87-BD4D-4ADA-95E0-C44EDB68914E

Q34431300-88341689-F436-4D1D-8D5F-78E516173DCF

Q34431300-9D1885A9-1613-4BBF-B9F7-B2E3A9F19931

Q34431300-F426BC21-D5D5-4028-B0FD-93ECCA330230

P2860

Q34431300-15FF8176-76AA-4CE3-A93F-8F19E5CCDE3C

Q34431300-2BD3C377-E8F4-4D34-A290-99714916DE96

Q34431300-366D6CC4-C04D-4EF9-972A-DB45E7F1A53F

Q34431300-6AA0B744-5E0D-45DE-A0B4-FBE4CA05785F

Q34431300-A5C69714-574F-4A3E-8A85-FF8390918682

Q34431300-BC5A9DCC-FB00-40C1-B948-1FDD7B8BD4B0

Q34431300-C4019B21-B5A2-4968-B061-F89DEB0B3B9D

Q34431300-DA3346BC-2749-476E-91C4-6DCD512659B4

Q34431300-EE1DDC8D-3AB2-4273-BCD3-35488AE97FA9

Q34431300-F34C1CC0-B3D4-45D8-9243-F756A0650528

P304

Q34431300-624B9CDC-6B5A-4A99-9677-0918EEA14514

P31

Q34431300-124FE2F4-E9CB-4F9A-AC2F-F0FC1716424F

P356

Q34431300-699D0C63-BD6A-4786-9A1F-F7362544E4C9

P407

Q34431300-3BEBF988-AFC7-4DC6-92C0-AA8A69E818F6

P433

Q34431300-9411E4F2-4B6B-4BB5-B628-54842FB5CB3C

P478

Q34431300-0E1DDDF3-221D-4888-A46C-AEC90AA92D33

P50

Q34431300-280EE3C0-2082-4D27-A955-1782F7274AD2

Q34431300-2F830303-A73E-41FA-A867-359E30767262

Q34431300-655FE4FA-6BB6-4A1E-A178-C48AB105EDA9

Q34431300-BBF64982-0F46-4939-B1C0-8EAA3E5686B3

P577

Q34431300-B6733584-6850-45C1-A48D-B65924A945F8

P5875

Q34431300-6C5D068C-4BF2-4743-B809-BDDF6327928E

P698

Q34431300-5F2B5E7D-AC10-4D0D-A976-3AD00C178957

P921

Q34431300-5439B46C-E129-43BF-A923-3ED46EE834F3

P932

Q34431300-C9AD16E2-8408-4763-9D65-FEEC56BEF1CB

P356

JNNP-2013-306936

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Efficacy and safety of nataliz ...... bservational programme results

@en

P2093

Annie Zhang

http://www.w3.org/2001/XMLSchema#string

Christophe Hotermans

http://www.w3.org/2001/XMLSchema#string

Fabio Pellegrini

http://www.w3.org/2001/XMLSchema#string

Ludwig Kappos

http://www.w3.org/2001/XMLSchema#string

Radhika N Patel

http://www.w3.org/2001/XMLSchema#string

TYSABRI Observational Program (TOP) Investigators

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

P304

1190-1197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP-2013-306936

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Helmut Butzkueven

P577

2014-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262046464

http://www.w3.org/2001/XMLSchema#string

P698

24532785

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4215289

http://www.w3.org/2001/XMLSchema#string